Dependency and analgesia related to treatment with subcutaneous octreotide in patients with growth hormone-secreting tumors

Endocrine Practice

Volumn 10, Issue 2, 2004, Pages 107-111

  Donangelo, Ines ^a   Rodacki, Melanie ^a   Peixoto, Maria Cláudia ^a   Vaisman, Mario ^a   Caldas, Nelson R ^a   Gadelha, Mônica R ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; HUMAN GROWTH HORMONE; OCTREOTIDE;

ADDICTION; ADENOMA; ADOLESCENT; ADULT; ARTICLE; CASE REPORT; DRUG TOLERANCE; FEMALE; HUMAN; HYPOPHYSIS TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; SECRETION;

ADENOMA; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; DRUG TOLERANCE; FEMALE; HUMAN GROWTH HORMONE; HUMANS; MIDDLE AGED; OCTREOTIDE; PITUITARY NEOPLASMS; SUBSTANCE-RELATED DISORDERS;

EID: 4344656343     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.10.2.107     Document Type: Article

References (16)

1. th ed. Philadelphia: WB Sauders, 2001:300-312.
2. th ed. New York:McGraw-Hill:, 2001:173-216.
3. May A, Lederbogen S, Diener HC. Octreotide dependency and headache: a case report. Cephalalgia. 1994;14:303-304.
4. Pascual J, Freijanes J, Berciano J, Pesquera C. Analgesic effect of octreotide in headache associated with acromegaly is not mediated by opioid mechanisms. Case report. Pain. 1991;47:341-344.
5. Musolino NR, Marino Junior R, Bronstein MD. Headache in acromegaly: dramatic improvement with the somatostatin analogue SMS 201-995. Clin J Pain. 1990;6:243-245.
6. Sicolo N, Martini C, Ferla S, et al. Analgesic effect of sandostatin (SMS 201-995) in acromegaly headache. Minerva Endocrinol. 1990;15:37-42.
7. Chrubasik J, Meynadier J, Blond S, et al. Somatostatin, a potent analgesic. Lancet. 1984;2:1208-1209.
8. Schmidt K, Althoff PH, Harris AG, et al. Analgesic effect of somatostatin analogue octreotide in two acromegalic patients: a double blind study with long-term follow up. Pain. 1993;53:223-227.
9. Lamberts SWJ. Non pituitary actions of somatostatin. A review on the therapeutic role of SMS 201-995 (sandostatin). Acta Endocrinol. 1987;276:41S-55S.
10. Maurer R, Gaehwiler BH, Buescher HH, et al. Opiate antagonistic properties of an octapeptide somatostatin analog. Proc Natl Acad Sci USA. 1982;79:4815-4817.
11. Paunovic VR, Popovic V. The development of dependence to an octapeptide somatostatin analog: contribution to the study of somatostatin analgesia. Biol Psychiatry. 1989;26: 97-101.
12. Gadelha MR, Prezant TR, Une KN, et al. Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene. J Clin Endocrinol Metab. 1999;84:249-256.
13. Wass JAH, Popovic V, Chayvialle J. Proceedings of the discussion: tolerability and safety of sandostatin. Metabolism. 1992;41:80S-82S.
14. Sassolas G, Harris AG, James-Deidier A, et al. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. J Clin Endocrinol Metab. 1990;71:391-397.
15. Kiang JG, Wei ET. Inhibition of an opioid evoked vagal refl ex in rats by naloxone, SMS 201-995 and ICI 154, 129. Regul Pept. 1983;6:255-262.
16. Guyton AC. The nervous system: General Principles and Sensory Physiology. In: Guyton AC, ed. Textbook of medical physiology. 8th ed. Philadelphia: WB Saunders, 1991;520-525.